A combination of Bristol-Myers Squibb's Opdivo and Yervoy has shown a significant response in patients with metastatic castration-resistant prostate cancer.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.